News

Filter events

Pages

  • Kurma Partners announces the launch of its third fund  Kurma Diagnostics (KDx). Institut Pasteur

    Press release | 26.05.2015

    Kurma Partners announces the launch of its third fund Kurma Diagnostics (KDx)

    The European Investment Fund (EIF), Fonds National d’Amorçage (FNA) managed by Bpifrance as part of the French government’s Investments for the future (“Investissements d’Avenir”) program, Institut Pasteur, and BNP Paribas are participating in the first closing (€33M). Kurma Diagnostics: the first Venture Capital fund dedicated to financing early-stage European innovative Diagnostic projects and companies.

  • Fibroblast from the skin of a patient with Cockayne syndrome. Premature aging: scientists identify and correct defects in diseased cells. © Institut Pasteur

    Press release | 18.05.2015

    Premature aging: scientists identify and correct defects in diseased cells

    Scientists have succeeded in restoring normal activity in cells isolated from patients with the premature aging disease Cockayne syndrome. They have uncovered the role played in these cells by an enzyme, the HTRA3 protease. This enzyme is overexpressed in Cockayne syndrome patient cells, and leads to mitochondrial defects, which in turn play a crucial role in the appearance of symptoms leading to aging in affected children.

  • Blood cells. Viagra to prevent transmission of the malaria parasite?  © 2015 Ramdani et al.

    Press release | 08.05.2015

    Viagra to prevent transmission of the malaria parasite?

    By increasing the stiffness of erythrocytes infected by the causal agent of malaria, Viagra favors their elimination from the blood circulation and may therefore reduce transmission of the parasite from humans to mosquitoes. This astonishing discovery could lead to a treatment to reduce the spread of malaria within a population.

  • Neurons. The Institut Pasteur and Stragen sign an exclusive worldwide license agreement for first-in-class pain management dual enkephalinase inhibitor (DENKI) novel compound.  © Institut Pasteur/Philippe Casanova

    Press release | 06.05.2015

    The Institut Pasteur and Stragen sign an exclusive worldwide license agreement for first-in-class pain management novel compound

    The Institut Pasteur, a private non-profit international biomedical research center based in Paris (France), and Stragen, privately-owned, international healthcare company based in Geneva (Switzerland), announced today that they have entered together into an exclusive worldwide license for intellectual property, related to derivatives of endogenous dual enkephalinase inhibitor (DENKI) novel compounds for pain management.

  • Practical class taking place at the Education center - The Médecine-Sciences Program: combining science and medicine to train tomorrow's leaders in biomedical research - Institut Pasteur

    Press release | 30.04.2015

    The Médecine-Sciences Program: combining science and medicine to train tomorrow's leaders in biomedical research

    Recent scientific breakthroughs and technological advances have fundamentally transformed the practice of medicine and biomedical research. To keep step with this changing environment, the École Normale Supérieure, the Institut Pasteur, the Institut Curie, ESPCI ParisTech, the Collège de France and PSL Research University have joined forces to offer students in medicine and pharmacy a new advanced program titled “Médecine-Sciences”.

  • Bacteriophages on bacteria. © Institut Pasteur

    Press release | 16.04.2015

    Ferring and the Institut Pasteur collaborate in novel IBD drug development project

    Ferring Pharmaceuticals a research-driven, specialty biopharmaceutical group and the Institut Pasteur, a non-profit international biomedical research center in Paris (France) today announced a collaboration aimed at identifying and developing bacteriophages to treat patients suffering from inflammatory bowel disease (IBD).

  • DNA sequencing. © Institut Pasteur

    Press release | 24.03.2015

    The Institut Pasteur Announces an Alliance with IntegraGen to Strengthen its High-Throughput Sequencing Activities in Microbiology

    As a result of partnership agreement, IntegraGen will be the main operator of high-throughput sequencing activities for the French National Reference Center (NRC) and microbiological collections at the Institut Pasteur. High-throughput sequencing will be the reference tool for analysis, surveillance and diagnostic activities associated with the above in line with the public health mission of the Institute.

  • Photo taken using transmission electron microscopy with negative staining. © Institut Pasteur

    Press release | 17.03.2015

    Chambéry babies – Official recognition of the new bacterium identified by the Institut Pasteur, Rouxiella chamberiensis

    Following the death of three newborns at Chambéry hospital (France) in December 2013, scientists at the Institut Pasteur quickly drew connections to a previously unknown bacterium responsible for the contamination of parenteral nutrition bags. Today, these scientists are publishing an article to announce the official recognition and complete characterization of this bacterium, which belongs to an entirely new genus. In homage to Emile Roux, a close collaborator of Louis Pasteur and head of the Institut Pasteur from 1904 to 1933, the bacterium was named Rouxiella chamberiensis. All of the data obtained through the sequencing and characterization of this bacterium have been made available to the wider scientific and medical community.

  • Viral particles on the cell surface of Chikungunya virus-infected fibroblasts

    Press release | 02.03.2015

    Themis Bioscience’s Chikungunya Vaccine Study Results Published

    Phase 1 trial of the vaccine candidate which was developed under an R&D collaboration between Themis Bioscience GmbH and the Institut Pasteur (Paris) shows good immunogenicity, safety and tolerability.

  • Press release | 03.02.2015

    Moderna and Institut Pasteur Sign Strategic Research Collaboration

    Moderna Therapeutics, a pioneer in the development of messenger RNA (mRNA) Therapeutics™ and the Institut Pasteur, today announced a long-term strategic research collaboration for the discovery and development of drugs and vaccines using Moderna’s mRNA Therapeutics™ platform. Valera, a Moderna venture company, will manage the research collaboration for Moderna.

Pages

Spécial ISF 2015 - Faites un don déductible à 75% de l'ISF - Institut Pasteur

donation_form_widget.jpg

Zoom in on...

Pasteur museum

Welcome to Pasteur Museum


musee-institut-pasteur.jpg


The Pasteur Museum is located at the Institut Pasteur, situated at: 25 rue du Docteur Roux 75015 Paris, France
 

Pasteur Museum